Tyrosine kinase inhibitors for gastrointestinal stromal tumor after imatinib resistance

Last Updated: Wednesday, August 6, 2025

Gastrointestinal stromal tumors, common GI mesenchymal tumors, are driven by KIT/PDGFRA mutations. While imatinib significantly transformed treatment, resistance poses ongoing challenges. Subsequent approved therapies include sunitinib, regorafenib, and ripretinib. Avapritinib is notable for PDGFRA D842V mutations, and other agents and investigational compounds are being explored. Future strategies focus on precision medicine to overcome evolving resistance and optimize treatment.

Pharmaceutics

Langenbeck's Archives of Surgery

Partial resection of rectum for rectal GIST by posterior approach

Clinical and Translational Medicine

Beta-elemene promotes ferroptosis to improve the sensitivity of imatinib in gastrointestinal stromal tumours by targeting N6AMT1

Endoscopy International Open

Feasibility and safety of endoscopic resection for duodenal gastrointestinal stromal tumors

Pediatrics

Complete remission of metastatic GIST in a pediatric patient with high-dose imatinib induction

Clinical Cancer Research

Phase 2 trial of ponatinib in patients with metastatic gastrointestinal stromal tumor following failure or intolerance of prior therapy with imatinib (POETIG trial)

Oncology Letters

Prolonged survival of a case with three different malignancies - cutaneous malignant melanoma, gastrointestinal stromal tumor and thyroid papillary cancer: A case report

Pharmaceutics